In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, ...

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...

Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...

Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...

Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.

Pfizer (PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to induce ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have been assigned a consensus rating of “Buy” from the fourteen analysts that are presently covering the company, MarketBeat.com reports.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...